Effects of metformin on brown fat of patientes with Polycystic Ovary Syndrome
Not Applicable
Recruiting
- Conditions
- Polycystic Ovary SyndromeC04.182.612.765
- Registration Number
- RBR-47tvky
- Lead Sponsor
- Hospital das Clínicas da Universidade Federal de Minas Gerais
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Premenopausal women diagnosed with polycystic ovary syndrome using the Rotterdam criteria (2003)
Exclusion Criteria
Use of antiandrogen medication in the last six months or hormones, including hormonal contraceptives, or metformin in the last two months. Obesity grade II or higher, defined as body mass index greater than 35 kg / m2. Pregnancy, postpartum and lactation. Diabetes.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in serum irisin levels and brown fat tissue volume after eight weeks of use of metformin or placebo in relation to pre-intervention values. The methods used to assess outcomes will be enzyme immunoassay (for serum irisin) and positron-emission tomography (brown adipose tissue).
- Secondary Outcome Measures
Name Time Method Improved metabolic profile and reduced body weight after eight weeks of use of metformin or placebo from pre and post intervention or observation period